- A small Japanese randomized controlled trial suggests that guselkumab (Tremfya) is associated with good efficacy and safety in patients with moderate to severe palmoplantar pustulosis (PPP).
Why this matters
- Study suggests that guselkumab, an anti-IL-23 monoclonal antibody, may represent a good therapeutic option for patients with moderate to severe PPP.
- Guselkumab patients had better improvements in mean PPP severity index total scores compared with placebo patients at week 16 (−3.3 vs −1.8; P=.03).
- Guselkumab patients had significantly better improvements in mean PPP area and severity index score (−10.2 vs −6.4; P=.009) and proportion of patients achieving 50% improvement in PPP area and severity index score (60% vs 21%; P=.009) compared with placebo patients at week 16.
- Guselkumab and placebo patients had similar rates of treatment-emergent adverse events (76% vs 75%).
- 49 patients with moderate to severe PPP, 41 who completed the study at week 24, were randomly assigned 1:1 to receive guselkumab or placebo at week 0 and 4 and analyzed for efficacy and safety outcomes.
- Funding: Janssen Pharmaceutical K.K., Tokyo, Japan.
- Small patient sample size.
- Short treatment period with only 2 doses.